Author of

• 20194

  +

  P3.15 - SCLC/Neuroendocrine Tumors (ID 731)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: SCLC/Neuroendocrine Tumors
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24217

    +

    P3.15-010 - Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Natural History of the Disease Progression and Management (ID 10394)

    09:30 - 09:30  |  Presenting Author(s): Zin Myint
    • Abstract
    • Slides

    Background:
    Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare, often benign pulmonary condition which is characterized by diffuse proliferation of neuroendocrine cells in respiratory epithelium. DIPNECH lesions are less than 5 mm in size and are limited to the basement membrane without any invasion. There is limited evidence regarding epidemiology, natural history of disease progression and management of this rare entity. We would like to present our single center experience.
    
    Method:
    Retrospective record based descriptive study of all DIPNECH patients managed at University of Kentucky Markey Cancer Center over past 5 years.
    
    Result:
    Our patient cohort had 8 females and one male with mean age of 64.5 years at the time of diagnosis. Dyspnea on exertion and dry cough were the commonest presenting symptoms. Three patients were under surveillance without treatment, two patients were treated with short acting somatostatin analog, another three were treated with long acting monthly somatostatin analogs and azithromycin combination, one patient got long acting somatostatin analog and everolimus combination. Two patients had concomitant well-differentiated neuroendocrine tumor of lung.
    
    Conclusion:
    DIPNECH is a rare pathology which can have profound effects on patient’s quality of life. Paroxysmal coughing spells can be difficult to treat. Our limited single center experience shows encouraging response to use of somatostatin analog, azithromycin and everolimus in the management of debilitating DIPNECH associated symptoms.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.